In vivo and in vitro impact of miRNA-153 on the suppression of cell growth apoptosis through mTORC2 signaling pathway in breast cancer

References

• Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15(5):R92–R92.
   PubMed Web of Science ®Google Scholar
• Qin WY, Feng SC, Sun YQ, et al. MiR-96-5p promotes breast cancer migration by activating MEK/ERK signaling. J Gene Med. 2020;22(8):e3188.
   PubMed Web of Science ®Google Scholar
• Li L, Yu J, Jiao S, et al. Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells. Onco Targets Ther. 2018; 11:8543–8553.
   PubMed Web of Science ®Google Scholar
• Medimegh I, Omrane I, Privat M, et al. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. PLOS One. 2014;9(11):e111877–e111877.
   PubMed Web of Science ®Google Scholar
• Jia L, Liu W, Cao B, et al. MiR-507 inhibits the migration and invasion of human breastcancer cells through flt-1 suppression. Oncotarget. 2016;7(24):36743–36754.
   PubMedGoogle Scholar
• Ma P, Ni K, Ke J, et al. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2. Exp Biol Med. 2018;243(5):473–480.
   Web of Science ®Google Scholar
• Zuo Z, Ye F, Liu Z, et al. MicroRNA-153 inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transition in breast cancer via direct targeting of RUNX2. Exp Ther Med. 2019;17(6):4693–4702.
   PubMed Web of Science ®Google Scholar
• Liang H, Xiao J, Zhou Z, et al. Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis. Oncogene. 2018;37(15):1961–1975.
   PubMed Web of Science ®Google Scholar
• Liang H, Ge F, Xu Y, et al. miR-153 inhibits the migration and the tube formation of endothelial cells by blocking the paracrine of angiopoietin 1 in breast cancer cells. Angiogenesis. 2018;21(4):849–860.
   PubMed Web of Science ®Google Scholar
• Zhang L, Pickard K, Jenei V, et al. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 2013;73(21):6435–6447.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zhao J, Yi L, et al. microRNA-153 targets mTORC2 component rictor to inhibit glioma cells. PLoS One. 2016;11(6):e0156915.
   PubMed Web of Science ®Google Scholar
• Ozkan G, Ulusoy S, Geyik E, et al. Down-regulation of miRNA 145 and up-regulation of miRNA 4516 may be associated with primary hypertension. J Clin Hypertens. 2019;21:1724–1731.
   PubMed Web of Science ®Google Scholar
• Lan H, Lu H, Wang X, et al. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015; 2015:125094–125094.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang K-Y, Liu S-M, et al. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 2014;19(2):1912–1938.
   PubMed Web of Science ®Google Scholar
• Niu G, Li B, Sun L, et al. MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-β2. PLOS One. 2015;10(3):e0119225.
   PubMed Web of Science ®Google Scholar
• Zhang W, Mao S, Shi D, et al. MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-Dioxygenase 1. Front Oncol. 2019;9:619–619.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang C, Meng Q, et al. miR-153 promotes neural differentiation in the mouse hippocampal HT-22 cell line and increases the expression of neuron-specific enolase. Mol Med Rep. 2019;20(2):1725–1735.
   PubMed Web of Science ®Google Scholar
• Huang M, Li C, Kong F, et al. Prognostic and clinicopathological significance of MicroRNA-153 in human cancers: a meta-analysis. Medicine. 2020;99(46):e22833.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu N, Zhang J, et al. MiR-153-5p enhances the sensitivity of triple-negative breast cancer cells to paclitaxel by inducing G2M phase arrest. Onco Targets Ther. 2020;13:4089–4097.
   PubMed Web of Science ®Google Scholar
• Wang B, Teng Y, Liu Q. MicroRNA-153 regulates NRF2 expression and is associated with breast carcinogenesis. Clin Lab. 2016;62(1–2):39–47.
   PubMed Web of Science ®Google Scholar
• Liu R, Chen H, Zhao P, et al. Mifepristone derivative FZU-00,003 suppresses triple-negative breast cancer cell growth partially via miR-153-KLF5 axis. Int J Biol Sci. 2020;16(4):611–619.
   PubMed Web of Science ®Google Scholar
• Shi D, Li Y, Fan L, et al. Upregulation of miR-153 inhibits triple-negative breast cancer progression by targeting ZEB2-Mediated EMT and contributes to better prognosis. OTT. 2019;12:9611–9625.
   Google Scholar
• Chen Y, Feng F, Gao X, et al. MiRNA153 reduces effects of chemotherapeutic agents or small molecular kinase inhibitor in HCC cells. Curr Cancer Drug Targets. 2015;15(3):176–187.
   PubMed Web of Science ®Google Scholar
• Wang J, Liang S, Duan X. Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-β) signaling pathway. J Cell Biochem. 2019;120(6):9539–9546.
   PubMed Web of Science ®Google Scholar
• Wu X, Li L, Li Y, et al. MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3. Am J Cancer Res. 2016;6:1563–1571.
   PubMed Web of Science ®Google Scholar
• Anaya-Ruiz M, Cebada J, Delgado-López G, et al. miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line. Asian Pac J Cancer Prev. 2013;14(5):2983–2986.
   PubMedGoogle Scholar
• Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2017;36(16):2191–2201.
   PubMed Web of Science ®Google Scholar
• Chen Z, Kang X, Wang L, et al. Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure. J Biol Chem. 2015;290(10):6387–6396.
   PubMed Web of Science ®Google Scholar
• Bracho-Valdés I, Moreno-Alvarez P, Valencia-Martínez I, et al. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused. IUBMB Life. 2011;63(10):896–914.
   PubMed Web of Science ®Google Scholar
• Song J-L, Chen C, Yuan J-P, et al. Progress in the clinical detection of heterogeneity in breast cancer. Cancer Med. 2016;5(12):3475–3488.
   PubMed Web of Science ®Google Scholar
• Zhang W, Dong YZ, Du X, et al. MiRNA-153-3p promotes gefitinib-sensitivity in non-small cell lung cancer by inhibiting ATG5 expression and autophagy. Eur Rev Med Pharmacol Sci. 2019;23(6):2444–2452.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Sun J, Bai Z, et al. MicroRNA-153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion. Onco Targets Ther. 2015;8:357–364.
   PubMed Web of Science ®Google Scholar